{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"study_type":["Other"],"full_dataset_link":["https://ega-archive.org/studies/EGAS00001002864"],"host":["EGA"],"description":["EGA study EGAS00001002864"],"dataset_title":["WGS and WES data for manuscript titled: ctDNA as a biomarker of progression in oesophageal adenocarcinoma","Dataset for manuscript titled: Spatial Intra-Tumour Heterogeneity and Treatment-Induced Genomic Evolution in Oesophageal Adenocarcinoma: Implications for Prognosis and Therapy","20180221_EGA_OESO","WGS data for manuscript titled: Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy","RNA-Seq data for manuscript titled: Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy"],"category":["restricted"],"repository":["EGA"],"name_synonyms":["primary cancer, Barretts esophagus, Malignant Neoplasm, Genomes, determination, Malignancy, Barrett esophagus, adenocarcinoma of oesophagus, Neoplasms, Benign Neoplasm, Benign Neoplasms, whole genome, Cancers, Barretts oesophagus, Tumor, Malignant, malignant tumor, Malignant Neoplasms, Neoplasias, Barrett metaplasia, MT, Benign, malignant neoplasm, chemical analysis, Barretts syndrome., Neoplasm, Barrett's epithelium, Barrett's oesophagus, Malignancies, assay, Neoplasia, adenocarcinoma of esophagus, Cancer, Tumors"],"description_synonyms":["Biological Markers, Viral Marker, Antemortem Diagnosis, Surrogate Endpoints, PhrB photolyase activity, determination, HSN1E, Laboratory, Ass-1, Period Prevalence, neoplasia, Biochemical, Endpoint, Tumor, Serum, pigmented epithelium, Diagnosis, between brain, School-Age, Laboratory Markers, Point Prevalence, diseases, Biological, AA408052, Point Prevalences, symptoms, fold, diseases and disorders, 3, NUP96, Fs(3)Hor, epithelium, DiE, treatment, average, human disease, DmelCG2684, Prevalences, cell process disease, tumor disease, neoplasm (disease), pigmented retina, NTef2, Estimated, DNA cyclobutane dipyrimidine photolyase activity, SUPPRESSOR OF AUXIN RESISTANCE 3, ASS, Immune, Markers, malignant neoplasm, Viral Markers, disease management, Therapies, Homo sapiens disease, Malignancies, tumor, CXXC finger protein 9, Diagnose, adenocarcinoma of esophagus, Tumors, Therapy, screening, PRE, Prevalence, Barretts esophagus, anatomical protrusion, Viral, PLATEST, Surrogate Endpoint, deoxyribonucleic cyclobutane dipyrimidine photolyase activity, frequency, neoplastic disease, Biochemical Markers, Biologic Marker, tumours, Diagnoses, Fs(3)Sz11, betweenbrain, Programs, mature diencephalon, Benign, Postmortem, Screenings, retinal pigment, Marker, School Age, Examinations and Diagnoses, Diseases, dipyrimidine photolyase (photosensitive), Barrett's oesophagus, median, Postmortem Diagnosis, retinal pigment layer, Diagnoses and Examination, Populations, ADCADN, Postmortem Diagnoses, death rate, UNQ203/PRO229, End Points, adenocarcinoma of oesophagus, DNA (cytosine-5-)-methyltransferase 1, signs, Benign Neoplasms, Immunologic, Laboratory Marker, surveillance, Treatments, morbidity, early, Malignant Neoplasms, disease, phr A photolyase activity, DNA-photoreactivating enzyme, Patient, spine, Biochemical Marker, Horka, CG2684, Fs(3)Horka, School-Age Population, other neoplasm, Platelets, other disease, Clinical Markers, Clinical Marker, Neoplasms, Benign Neoplasm, Period Prevalences, photoreactivating enzyme activity, Malignant, interbrain, NEOPL, protrusion, Surrogate End Points, Surrogate Markers, Aim, AIM, Mass, Screening, disease or disorder, Barrett's epithelium, stratum pigmentosa retinae, DmF2, Antemortem, increase in risk, neoplasm, lod, School-Age Populations, DNMT1, Biomarker, MOS3, deoxyribocyclobutadipyrimidine pyrimidine-lyase activity, Clinical, Malignancy, Barrett esophagus, PRECOCIOUS, DNMT1_HUMAN, occurrence, Biological Marker, prevalence, F23A5.3, tumour, Diagnoses and Examinations, Population, non-neoplastic, Neoplasias, API6, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS), Barrett metaplasia, Immunologic Markers, time of survival, Clients, Barretts syndrome, disorder, School Age Population, Immunologic Marker, F23A5_3, Neoplastic Growth, incidence, Biologic, Cancer, DNA MTase HsaI, DNA (cytosine-5)-methyltransferase 1, Antemortem Diagnoses, findings, Malignant Neoplasm, Serum Markers, diencephalon, disorders, DNMT, End Point, thalamencephalon, medical condition, MCMT, Client, Examination and Diagnoses, Immune Marker, MODIFIER OF SNC1, neoplastic growth, disease management., survival, MT, Period, Mass Screenings, Surrogate End Point, DNA methyltransferase HsaI, chemical analysis, deoxyribonucleic photolyase activity, Neoplasm, condition, outbreaks, Biologic Markers, CXXC9, primary cancer, Serum Marker, RPE, CT-2, photolyase activity, Surrogate, Endpoints, Cancers, Barretts oesophagus, Lds, disease of cellular proliferation, malignant tumor, School Age Populations, CXXC-type zinc finger protein 9, endemics, Surrogate Marker, p. pigmentosa retinae, Therapeutic, Point, Treatment, epidemics, deoxyribonucleate pyrimidine dimer lyase (photosensitive), assay, Neoplasia, NEOPLASMS BENIGN, CLEC2C, m.HsaI, Immune Markers"],"additional_accession":[]},"is_claimable":false,"name":"Genome analysis of oesophageal cancer and Barrett's oesophagus","description":"The median survival of oesophageal cancer this year is only 13 to 19 months after diagnosis and more than 90% will die from their disease. Therefore better treatment options are needed. The likelihood of cure for early screen-detected cancers is much higher. Barrett's oesophagus is a pre-cancerous lesion associated with a 30-40 fold increased risk of developing cancer. In an attempt to detect cancer early many patients with Barrett's are enrolled into surveillance programs involving regular endoscopies. A major problem with this approach is that the prevalence of BO in the population is estimated to be around 2%, but most patients with BO will never develop cancer. We are undertaking genomic and/or transcriptomic analysis of oesophageal tumours, Barrett's oesophagus and matched normal samples. The aim is to identify oesophageal-related genomic and transcriptomic alterations, which may reveal mutational process occurring, suggest biomarkers of tumour progression and treatment and identify novel treatment strategies.","dates":{"updated":"2024-08-13 12:15:52"},"accession":"EGAS00001002864","cross_references":{"TAXONOMY":["9606"],"EGA":["EGAD00001008554","EGAD00001008656","EGAD00001003996","EGAD00001015373","EGAD00001008646","EGAC00001003487","EGAC00001000863"]}}